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ABSTRACT. Objective: The purpose of this study was to compare the 
prevalence of psychoactive substances in general traffi c in The Nether-
lands and Belgium. Method: Randomly selected car drivers and drivers 
of small vans in six police regions in The Netherlands and fi ve police 
regions in Belgium were included between January 2007 and August 
2009. Blood and oral fl uid samples were analyzed for 23 substances, 
including ethanol (alcohol), by means of ultra performance liquid 
chromatography–tandem mass spectrometry or gas chromatography–
mass spectrometry analysis. Samples were weighted according to the 
distribution of traffi c over eight 6-hour periods. Substance groups were 
categorized in fi ve mutually exclusive classes: single alcohol use, single 
illicit drug use, single medicinal drugs use, multiple drug use (includ-
ing drugs from two or more separate substance groups but excluding 
alcohol), and drug use (either single or multiple) in combination with 
alcohol. Results: In total, 7,771 drivers (4,822 in The Netherlands and 
2,949 in Belgium) were included in the study. In Belgium, the prevalence 
of single alcohol (6.4%) and single medicinal drugs (3.0%) was much 
higher than in The Netherlands (2.2% and 0.6%, respectively), whereas 
the single illicit drugs were more common in Dutch traffi c (2.2%) than 
in Belgian traffi c (0.6%). Compared with the estimated prevalence of 
psychoactive substances in the general driving public in Europe, the 
prevalence in Belgium (10.7%) was greater than the European average 
(7.4%), and the prevalence in The Netherlands was below the European 
average (5.5%). Conclusions: The observed prevalence of psychoac-
tive substances varies largely between The Netherlands and Belgium. 
Probable reasons for the differences are the higher level of alcohol 
enforcement in The Netherlands and nonresponse bias in the Belgian 
study (for illicit drugs in particular). Furthermore, cultural differences 
and variances in prescription policy could also be infl uential. (J. Stud. 
Alcohol Drugs, 73, 000–000, 2012)
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ALTHOUGH THE USE OF PSYCHOACTIVE sub-stances by motor vehicle drivers is suspected as a 
major risk factor in traffi c, valid information on psychoac-
tive substance use by motorists is sparse (Behrensdorff and 
Steentoft, 2003; European Monitoring Centre for Drugs and 
Drug Addiction, 2008). Prevalence studies are, in general, 
complex and expensive to conduct, partly because of the 
relatively low incidence of psychoactive substances in traffi c. 
For a study to have enough statistical power, many drivers 
need to be included.
 Review studies report a large variation of drivers in gen-
eral traffi c positive for one or more psychoactive substances 
other than alcohol. It is diffi cult to directly compare the 
results of these roadside surveys because of differences in 
study design, such as the number of substances included, 
the analytical cutoff levels applied, and the biological ma-
trix used (European Monitoring Centre for Drugs and Drug 
Addiction, 2008; Kelly et al., 2004; Walsh et al., 2004). In 
Norway, 4.5% of motor vehicle drivers were positive for 
psychoactive substances including illicit drugs, medicinal 
drugs, or alcohol (Gjerde et al., 2008). In Thailand, 5.5% of 
drivers tested positive for alcohol, and 9.7% of drivers were 
positive for other psychoactive substances (Ingsathit et al., 
2009). In the state of Victoria, Australia, 2.4% of drivers 
were positive for methamphetamines, 3,4-methylenedioxy-
methamphetamine (MDMA, or Ecstasy), or tetrahydrocan-
nabinol (THC, or cannabis). In the United States, 11% of 
drivers were positive for illicit and medicinal drugs during 
daytime hours on Friday and 14.4% during nighttime hours 
on Friday and Saturday nights (Lacey et al., 2009). In British 
Columbia, 10.4% of drivers tested positive for drug use on 
Wednesday and Saturday nights.
 In the European research project DRUID (Driving Under 
the Infl uence of Drugs, Alcohol and Medicines), prevalence 
studies have been conducted from 2007 to 2009 in 13 Eu-
ropean countries (Houwing et al., 2011a, 2011b). Special 
attention was given to the comparability of these studies by 
using a common study design (Assum et al., 2007), which 
included recommendations on the type of road users and 
substances to be included, as well as the cutoff levels of 
these substances. Despite recommendations for a common 
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design, some differences could not be ruled out for practical, 
legislative, or medical ethical reasons. The main difference 
in the design of these 13 studies was that some countries 
used blood as the biological matrix, some used oral fl uid, 
and some used a combination of both. To be able to compare 
the results from countries that used blood with countries that 
used oral fl uid, equivalent cutoffs were applied, as reported 
by Verstraete et al. (2011b) and Gjerde et al. (2010). When 
using equivalent cutoff concentrations in blood and oral 
fl uid, the prevalence of a drug will be equal in samples of 
blood and samples of oral fl uid when studying a large co-
hort. Based on the outcomes of these 13 studies and after 
application of weighing factors for country size and size 
of the represented European regions, it was estimated that 
an average of 1.89% of the drivers in the European Union 
were positive for illicit drugs, 1.39% for medicinal drugs, 
3.48% for alcohol, 0.39% for polydrug use, and 0.37% for 
the combined use of alcohol and other drugs (Houwing et 
al., 2011a).
 Belgium and The Netherlands are two neighboring 
countries in Western Europe that shared a common history 
until 1830, when Belgium separated from The Netherlands. 
Comparisons between Belgium and The Netherlands are 
commonly made because of their historical and cultural 
bonds. A comparison of Dutch and Belgian results is also 
interesting because they were the only two Western European 
countries that were involved in the DRUID roadside surveys. 
This article reports on and compares the use of psychoac-
tive substances in traffi c based on results of the Belgian 
and Dutch prevalence studies that were conducted in the 
European DRUID project. Furthermore, Dutch and Belgian 
results are compared with the estimated European mean and 
with previously conducted national studies in Belgium and 
The Netherlands on the use of psychoactive substances in 
traffi c.
Method
General design
 A cross-sectional roadside survey was conducted to deter-
mine the prevalence of psychoactive substances among the 
general driving population in Belgium and The Netherlands. 
A stratifi ed multistage sampling design was used. In the fi rst 
stage, fi ve study regions were selected in Belgium and The 
Netherlands. These regions were meant to be representative 
of the entire country with regard to substance use and traffi c. 
Within these regions, smaller research areas (fi ve Belgian 
and six Dutch police regions) were selected in the second 
stage. Within these areas, survey locations were selected in 
which car drivers and van drivers were randomly selected 
from actual traffi c between January 2007 and August 2009. 
For each police region, data were collected during several 
roadside survey sessions distributed over eight 6-hour periods 
covering all hours of the day on both weekdays and weekend 
days. The periods were distributed into type of day (weekday/
weekend day) and time of day (4:00 A.M.–9:59 A.M., 10:00 
A.M.–3:59 P.M., 4 P.M.–9:59 P.M., and 10 P.M.–3:59 A.M.).
 Drivers were stopped by the police at the request of the 
research coordinator. As soon as an interviewer/nurse was 
ready for interviewing and blood sampling, a driver (i.e., 
the next car approaching the research site) was stopped. 
Drivers who were stopped were asked to cooperate with the 
study on a voluntary basis. Drivers who agreed to cooperate 
were interviewed about their drug and medicine use. Apart 
from self-reported drug use and time of administration, data 
collection also comprised date and time of selection, gender 
and age of the subject, and signs of impairment. In Belgium, 
all drivers were asked to provide both blood and oral fl uid 
samples. If drivers refused to give a blood sample, a single 
oral fl uid sample was requested. In the Belgian study, par-
ticipating drivers received a reward of €20. In the Dutch 
study, all drivers were asked to give a blood sample. If driv-
ers refused to give a blood sample, an oral fl uid sample was 
requested. Participants received a €5 reward for an oral fl uid 
sample and a €10 reward for a blood sample. In case drivers 
reported recent drug use, an additional oral fl uid sample was 
requested after collecting a blood sample.
 In The Netherlands as well as in Belgium, the breath test 
was compulsory for all drivers who were stopped. In The 
Netherlands, participants were breath tested for alcohol by a 
police offi cer after the interview and the blood or oral fl uid 
sampling. Drivers who refused to participate were breath 
tested for alcohol by a police offi cer, and, if possible, ad-
ditional information was collected including information on 
age, gender, clinical signs of impairment, and reason for re-
fusal. In Belgium, all drivers who were stopped were breath 
tested before the request regarding participation in the study.
Ethical approval
 In Belgium, the protocol was approved by the ethics com-
mittee of Ghent University Hospital. Participants needed to 
sign an informed consent. No ethical approval was needed 
in The Netherlands. After having been informed about the 
project, the ethics committee made clear that “the project 
is not encompassed by the law on ethics committees and 
consideration regarding bio-medical research projects. There-
fore, the project does not have to be announced to the ethics 
committee.” Hence, no informed consent was requested. 
However, participants in The Netherlands were informed 
both in writing and by oral communication about the study 
and its voluntary nature.
Sample preparation and analysis
 Venous blood samples were collected in glass tubes con-
taining 20 mg sodium fl uoride and 143 IU heparin sodium 
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(BD Plymouth, Brest, The Netherlands, and Terumo, Leu-
ven, Belgium). In The Netherlands, oral fl uid samples were 
taken by having the participant spit into a polypropylene 
container (Deltalab, Barcelona, Spain). In Belgium, oral fl uid 
samples were collected by using the StatSure Saliva Sampler 
(StatSure Diagnositc Systems, Inc., Brooklyn, MA). In The 
Netherlands, estimated blood alcohol concentration (BAC) 
was measured with a handheld breath alcohol analyzer us-
ing a Dräger Alcotest 7410 Plus screening device (Dräeger 
Safety Inc., Lübeck, Germany). In Belgium, BAC was 
estimated from both oral fl uid and whole blood. For drivers 
from whom only oral fl uid samples were collected, results 
for ethanol (alcohol) in oral fl uid were converted using the 
following formula:
Calculated blood ethanol (%) = measured ethanol 
in oral fl uid (g/L) × 1.22.
The applied factor of 1.22 was based on the average conver-
sion factor between blood and oral fl uid that was calculated 
from the Belgian DRUID results of those drivers from whom 
both blood and oral fl uid samples were collected (Verstraete 
et al., unpublished observations).
 In Belgium, the following methods were used for toxico-
logical analysis of whole blood samples: an enzymatic meth-
od for ethanol analysis, a solid-phase extraction followed 
by ultra performance liquid chromatography–tandem mass 
spectrometry (UPLC-MS/MS) analysis for all substances 
except cannabinoids, enzyme-linked immunosorbent assay 
(ELISA) screening (qualitative) for cannabinoids, and liq-
uid–liquid extraction followed by gas chromatography–mass 
spectrometry analysis for samples that gave positive results 
at the ELISA screening for cannabinoids.
 An enzymatic method for ethanol analysis and protein 
precipitation, followed by UPLC-MS/MS for all other 
substances, was used for the Dutch toxicological analysis 
of whole blood samples. Four rounds of profi ciency test-
ing were organized in the participating countries during the 
study.
 In The Netherlands, the conversion factor of breath 
alcohol concentrations into BACs in percentages is 1:23 
(Mathijssen and Twisk, 2001). However, in other European 
countries that were involved in the DRUID roadside surveys, 
a higher conversion factor of 1:21 is used (Melethil, 2011). 
To be able to compare the Dutch alcohol results with the 
results for other European Union countries, all BAC results 
from The Netherlands were multiplied by a factor of 1.095 
(23 / 21).
Equivalent cutoffs
 In total, 23 substances were included in the analysis. 
Selection of these substances was based on their prevalence 
of use in the general population and their possible infl uence 
on driving ability. Results were presented by using equiva-
lent cutoffs. When using equivalent cutoff concentrations in 
blood and oral fl uid, the prevalence of a drug will be equal 
in samples of blood and samples of oral fl uid when studying 
a large cohort. The reason for applying equivalent cutoffs is 
that, for many substances, concentrations in oral fl uid are 
much higher than in blood, whereas for some compounds 
the concentrations are lower (Verstraete et al., 2011b). Table 
1 provides an overview of the applied cutoff concentrations. 
In case both blood and oral fl uid samples were available, the 
result from the blood analysis was leading.
Substance groups and classes`
 For calculating prevalence, substances of the same type 
were aggregated into substance groups. All groups were 
mutually exclusive, meaning that each record was either neg-
ative or linked to one of the following groups: alcohol, am-
phetamines, cocaine, THC, illicit opiates, benzodiazepines, 
Z drugs (nonbenzodiazepine medications mainly used for the 
treatment of insomnia), and medicinal opioids. Samples in 
which only THC-COOH (11-nor-9-carboxy-THC; a metabo-
lite of THC that is detectable in blood and that occurs in very 
TABLE 1. Applied cutoffs for psychoactive substances other than alcohol; 
THC-COOH is not included in this table because THC-COOH was not 
analyzed in oral fl uid
 Cutoff in oral Cutoff in whole
Substance group/substance fl uid (ng/mL) blood (ng/mL)
Amphetamines
 Amphetamine 360 20
 Methamphetamine 410 20
 MDA 220 20
 MDEA 270 20
 MDMA 270 20
Cocaine
 Cocaine 170 10
 Benzoylecgonine 95 50
Cannabis
 THC 27 1.0
Illicit opiates
 6-Acetylmorphine 16 10
Benzodiazepines
 Diazepam 5.0 140
 Flunitrazepam 1.0 5.3
 Lorazepam 1.1 10
 Alprazolam 3.5 10
 Clonazepam 1.7 10
 Nordiazepam 1.1 20
 Oxazepam 13 50
Medicinal opioids
 Methadone 22 10
Medicinal opioids or illicit opiates
 Morphine 95 10
 Codeine 94 10
Z drugs
 Zolpidem 10 37
 Zopiclone 25 10
Notes: TCH-COOH = 11-nor-9-carboxy-tetrahydrocannabinol; MDA = 
methylenedioxyamphetamine; MDEA = 3,4-methylenedioxy-N-ethyl-
amphetamine; MDMA = 3,4-methylenedioxymethamphetamine; THC = 
tetrahydrocannabinol.
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low concentrations in oral fl uid) was detected were regarded 
as negative. Samples that included substances from two or 
more substance groups were included either in the drug–
drug combination group or in the alcohol–drug combination 
group, depending on the presence of alcohol. More detailed 
information on the aggregation into substance groups and 
classes can be found in Houwing et al. (2011a).
 Morphine and codeine concentrations could be classifi ed 
as medicinal opioids or as illicit opiates. Morphine and co-
deine were regarded, in general, as medicinal opioids, except 
in those cases when they were detected in combination with 
each other and when the concentration of morphine was 
higher than the concentration of codeine. A higher concen-
tration of morphine would suggest the use of an illicit opiate 
such as heroin.
Weighing factors
 Because random sampling was applied, drivers were 
expected to be representative of gender and age during 
sampling sessions. However, because police preferences 
had to be considered, the selection of samples could not be 
distributed equally with traffi c volumes over the different 
periods. To correct for the difference between distribution of 
roadside samples and distribution of traffi c over eight differ-
ent periods, weight factors were calculated by dividing the 
general distribution of traffi c by period by the distribution of 
sampled drivers in the same period. The weighing procedure 
in The Netherlands was based on 2007–2008 national trip 
distribution data from the National Travel Survey collected 
by the Dutch Central Bureau of Statistics (Central Bureau 
of Statistics, 2011), and the weighing procedure in Belgium 
was based on 2007 traffi c counts from the Flemish Govern-
ment’s Agency for Roads and Traffi c (Agentschap Wegen en 
Verkeer, 2007).
Statistical analysis
 Weighted prevalence was calculated by using descriptive 
statistics by means of the statistical software SAS Version 
9.2 (SAS Institute, Cary, NC). Tables were created by using 
a FREQ procedure including a statement on the weight fac-
tors to be used. Weighted prevalence of the substance under 
scrutiny was calculated by dividing the weighted number of 
positives for this substance by the weighted total of samples. 
For calculating confi dence intervals, the Wilson confi dence 
interval formula (Wilson, 1927) was used because lower and 
upper confi dence limits calculated using traditional approxi-
mations may result in limits outside the (0,1) interval. Pos-
sible differences in substance use between the two countries 
were investigated with binomial logistic regression in SPSS 
Version 16.0.1 (SPSS Inc., Chicago, IL). Type of country 
was used as a covariate (with two categories: 0 = Belgium, 
1 = The Netherlands), and each substance was included as a 
dependent variable (also with two categories: 0 = negative, 
1 = positive). In all statistical tests, the conventional critical 
5% level was used to assess whether the obtained odds ratio 
(OR) signifi cantly deviated from 1.
Results
Study population
 In The Netherlands, 5,064 drivers were asked to par-
ticipate in this study. Of these drivers, 242 (4.8%) declined 
and 4,822 (95.2%) agreed to participate. In Belgium, 6,155 
drivers were asked to participate. Of these drivers, 3,206 
(52.1%) refused and 2,949 (47.9%) agreed to participate. 
Of the 4,822 participating drivers in the Dutch study, 3,476 
(72%) provided a blood sample, 1,068 (22%) provided an 
oral fl uid sample, and 278 (6%) provided both a blood and 
an oral fl uid sample. As stated previously, in case both blood 
and oral fl uid samples were collected, the results of the blood 
analysis were leading. In the Belgian study, 2,750 (93%) of 
the 2,949 participating drivers provided both blood and oral 
fl uid samples, and 199 (7%) provided an oral fl uid sample 
only. Table 2 provides an overview of the distribution of the 
participating drivers by age and gender. No information on 
age was available from 5 drivers in The Netherlands and 21 
drivers in Belgium.
 There was no signifi cant difference in the age and gender 
distribution between the two survey samples. Distribution 
TABLE 2. Distribution roadside survey sample by age and gender; excluding 5 missing values 
for respondents in The Netherlands and 21 missing values for respondents in Belgium
 The Netherlands Belgium
 respondents (n = 4,817) respondents (n = 2,928)
Age, in years Male Female Total Male Female Total
18–24 7.3% 3.2% 10.5% 6.3% 3.8% 10.1%
25–34 15.1% 5.9% 21.1% 12.6% 8.5% 21.5%
35–49 23.8% 12.0% 35.8% 25.3% 12.5% 37.8%
≥50 23.6% 9.0% 32.6% 22.7% 8.4% 31.1%
Total 69.8% 30.2% 100% 66.8% 33.2% 100.0%
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of drivers in the Dutch roadside sample was comparable 
with the national distribution on gender, which accounts for 
70.3% and 29.7% of male and female drivers, respectively 
(Central Bureau of Statistics, 2011 [National Traffi c Sur-
vey]; Dienst Verkeer en Scheepvaart, 2011 [Dutch Mobil-
ity Survey]. Distribution by gender in the Belgian DRUID 
study was comparable to the distribution found in the 2007 
Belgian roadside survey of drinking and driving, where 67% 
of the drivers were male and 33% of the drivers were female 
(DuPont, 2009).
 A comparison of the response group with the nonresponse 
group in the Belgian study (Houwing et al., 2011b) showed 
that there was a small but signifi cant overrepresentation of 
male drivers among the nonresponse group. This overrepre-
sentation was mainly present in the 25- to 34-year-old age 
group. The prevalence of illicit drugs was generally higher 
among young male drivers (Houwing et al., 2011a, 2011b). 
Furthermore, it was shown that from 4:00 A.M. to 9:59 A.M. 
on both weekday/weekend days and from 10:00 A.M. to 3:59 
P.M. on weekends, the refusal rates were highest. Alcohol 
prevalence among respondents did not differ with the preva-
lence found in nonrespondents (p = .321).
 The nonresponse rate in The Netherlands was only 4.8%. 
The prevalence of alcohol was slightly higher for the non-
response group than for the response group. However, the 
BAC distribution of the combined response and nonresponse 
group was almost identical to the BAC distribution of the 
response group alone. The self-reported use of psychoactive 
substances other than alcohol was higher for the nonresponse 
group. After correction for the unknown answers, 6.5% of 
the nonrespondents reported the use of psychoactive sub-
stances in the past 12 hours versus 3.6% of the respondents. 
When the self-reported use of the nonresponse group would 
have been added, the self-reported use of the total study 
population would increase just one tenth of a percentage 
point, from 3.6% to 3.7%.
Prevalence
 Table 3 provides a general overview of the prevalence 
of psychoactive substances in Dutch and Belgian traffi c. As 
mentioned above, the substance groups were divided into 
four drug categories: alcohol, illicit drugs, medicinal drugs, 
and combined use of drugs or drugs with alcohol.
 Alcohol. In both countries, single alcohol use (BAC > 
.01%) was the most prevalent substance. The prevalence of 
single alcohol use in Belgian traffi c (6.42%) was signifi cant-
ly higher (OR = 3.15, 95% CI [2.46, 4.03]) than in Dutch 
traffi c (2.15%) (Figure 1). For each of the three BAC groups, 
the prevalence in Belgium was at least twice as high as in 
The Netherlands. However, the relative difference decreased 
at higher BAC levels. Alcohol was used in combination with 
other psychoactive substances far less frequently than alone. 
In The Netherlands, the prevalence of alcohol in combina-
tion with other psychoactive substances was 0.24%, which 
was 10% of the total prevalence of alcohol. In Belgium, the 
prevalence of alcohol in combination with other substances 
was 0.31%, which was 5% of the total prevalence of alcohol.
 Illicit drugs. The illicit drug class consisted of four dif-
ferent illicit drug groups: amphetamines, cocaine, cannabis, 
and illicit opiates (Table 1). In The Netherlands, 2.17% of 
all drivers were positive for illicit drugs, whereas in Belgium 
the prevalence was lower, at only 0.64%, a signifi cant dif-
ference (OR = 0.27, 95% CI [0.16, 0.45]). THC was by far 
the most frequently detected illicit drug in The Netherlands 
(1.67%) and in Belgium (0.35%). The THC prevalence in 
Belgium was signifi cantly lower than in The Netherlands 
(OR = 0.21, 95% CI [0.11, 0.40]). Cocaine was detected 
among 0.30% of the drivers in The Netherlands and among 
0.20% of the drivers in Belgium (OR = 0.69, 95% CI [0.26, 
1.88]). This difference was not signifi cant. Amphetamines 
were detected among 0.19% of the Dutch drivers and were 
completely absent among the Belgian drivers. Because of 
TABLE 3. Adjusted general distribution of core substances including 95% confi dence intervals
  Prevalence Prevalence
  The Netherlands, % Belgium, %
Variable Substance group (n = 4,822) (n = 2,949)
Negative Negative 94.49 [93.81, 95.10] 89.35 [88.18, 90.41]
Alcohol Alcohol alone >.01% 2.15 [1.78, 2.60] 6.42 [5.59, 7.36]
 Alcohol .05%–.079% 0.26 [0.15, 0.44] 1.33 [0.97, 1.81]
 Alcohol .08%–.119% 0.14 [0.07, 0.29] 0.42 [0.24, 0.72]
 Alcohol ≥.12% 0.21 [0.12, 0.39] 0.41 [0.23, 0.71]
Illicit drugs THC alone 1.67 [1.34, 2.07] 0.35 [0.19, 0.64]
 Cocaine alone 0.30 [0.18, 0.50] 0.20 [0.09, 0.43]
 Amphetamines alone 0.19 [0.10, 0.36] .         –a
 Illicit opiates alone 0.01a [0.00, 0.09] 0.09a [0.03, 0.28]
Medicinal drugs Benzodiazepines alone 0.40 [0.25, 0.62] 2.01 [1.57, 2.59]
 Medicinal opioids alone 0.16 [0.08, 0.32] 0.75 [0.50, 1.13]
 Z drugs alone 0.04a [0.01, 0.15] 0.22 [0.10, 0.47]
Combinations Multiple drugs 0.35 [0.22, 0.56] 0.30 [0.16, 0.58]
 Alcohol–drugs 0.24 [0.13, 0.42] 0.31 [0.16, 0.58]
Notes: THC = tetrahydrocannabinol. aWeighted n < 5.
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the absence of amphetamines in the Belgian study sample, 
a value of 0.1 was added to each of the four cells (Agresti, 
1996), which resulted in a nonsignifi cant difference (OR = 
0.02, 95% CI [0.00, 8.97]) between the Dutch and Belgian 
prevalence. Illicit opiates were rarely present (0.01%) in The 
Netherlands and sparsely detected in Belgium (0.09%). This 
difference was not signifi cant either (OR = 11.11, 95% CI 
[0.29, 432.54]).
 Medicinal drugs. The medicinal drugs class consisted 
of three different drug groups: benzodiazepines, medicinal 
opioids, and Z drugs (see Table 1). Medicinal drugs were 
signifi cantly more prevalent in general traffi c in Belgium 
(2.98%) than in The Netherlands (0.60%) (OR = 6.40, 95% 
CI [4.00, 10.25]). The most frequently detected medicinal 
drugs were benzodiazepines. In The Netherlands, 0.40% 
of the drivers were screened positive for benzodiazepines, 
as did 2.01% in Belgium (OR = 5.16, 95% CI [3.08, 8.66]) 
(Figure 1). Medicinal opioids were detected relatively fre-
quently in Belgium (0.75%) but signifi cantly less in The 
Netherlands (0.16%) (OR = 4.60, 95% CI [2.04, 10.37]). Z 
drugs were signifi cantly more prevalent in Belgium (0.22%) 
than in The Netherlands (0.04%) (OR = 5.12, 95% CI [1.08, 
24.31]).
 Drug–drug and alcohol–drug combinations. Patterns of 
the prevalence of combinations of psychoactive substances 
were more or less the same in The Netherlands (0.24% 
alcohol–drugs and 0.35% drug–drug combinations) and 
in Belgium (0.31% alcohol–drugs and 0.30% drug–drug 
combinations). The corresponding odds ratios were not 
signifi cant (alcohol–drugs, OR = 1.37, 95% CI [0.62, 
3.00]; drug–drug combinations, OR = 0.76, 95% CI [0.34, 
1.71]). Both in Belgium and in The Netherlands, cocaine 
was detected with approximately the same frequency alone 
as it was in combination with other substances. For THC, 
Z drugs, and medicinal opiates and opioids, the share of 
combined use was approximately 25% of the total use, 
whereas for alcohol and benzodiazepines the propor-
tion was about 10% in both countries. For amphetamines 
(0.00% in Belgium) and illicit opiates (0.01% in The Neth-
erlands), the prevalence was too low to compare between 
countries.
Comparison with previous studies in The Netherlands and 
Belgium
 In The Netherlands, only one previous prevalence study 
had been conducted in the past 10 years on the prevalence 
of drugs and medicines in traffi c (Mathijssen and Houwing, 
2005). For alcohol prevalence, data were available on a 
yearly basis since 1974, but this information was only gath-
FIGURE 1. Prevalence of substances alone and in combination; prevalence in percentages. Combi = combination; BE = Belgium; NL = The Netherlands; ETH 
= ethanol (alcohol); AMP = amphetamines; COC = cocaine; THC = tetrahydrocannabinol (cannabis); OPI = illicit opiates; BDZ = benzodiazepines; ZDR = 
Z drugs; MOPI = medicinal opioids.
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ered during weekend nights (Dienst Verkeer en Scheepvaart, 
2011). For the prevalence of alcohol during other periods, 
only data from the European research project IMMORTAL 
(Impaired Motorists, Methods of Roadside Testing and 
Assessment for Licensing) were available (Mathijssen and 
Houwing, 2005).
 Between 2000 and 2004, a roadside survey was conducted 
in the Dutch Tilburg police district as part of the European 
IMMORTAL study. The prevalence of single illicit drugs 
was higher in the IMMORTAL study (4.5%) than it was in 
the Dutch DRUID study (2.17%). However, the results of 
the IMMORTAL study were mainly based on urine samples 
in which drugs are detectable for a longer period than in 
blood and oral fl uid (Verstraete, 2004). Therefore, a direct 
comparison between the prevalence rates of the IMMORTAL 
and DRUID studies was not possible.
 In Belgium, national data on the prevalence of alcohol 
in traffi c were available for the years 2003, 2005, and 2007 
(DuPont, 2009). No previous data were available on the 
prevalence of other psychoactive substances in traffi c. The 
prevalence of alcohol in the DRUID study was somewhat 
higher than the results from the biannual roadside survey on 
alcohol use, which found an average prevalence of 2% dur-
ing the whole week for a BAC of 0.5 g/L and higher. In the 
DRUID study, this prevalence was 2.33%. These results did 
not signifi cantly differ from each other.
Comparison with DRUID mean
 Within the DRUID project, a European mean was esti-
mated based on the prevalence of psychoactive substances in 
13 different European countries including The Netherlands 
and Belgium using a uniform study design (Houwing et al., 
2011). Figure 2 presents the comparison of the Dutch and 
Belgian prevalence data (including 95% confi dence inter-
vals) with the estimated European mean.
 The results show that the relative position of the Belgian 
and Dutch results toward the European mean was mirrored 
for all substances. Benzodiazepines, medicinal opiates 
and opioids, and alcohol were more frequently detected 
in Belgium as opposed to the European mean, whereas in 
The Netherlands they were less frequently detected than 
in Europe. However, the prevalence of amphetamines and 
THC in Dutch traffi c was above the European average, and 
the prevalence of these substances in Belgium was below 
average. The prevalence of cocaine, illicit opiates, Z drugs, 
alcohol–drugs, and drug–drug combinations in traffi c varied 
between the two countries; but, for all of these substances, 
FIGURE 2. Comparison of national prevalence in Belgium and The Netherlands for various groups of substances including 95% confi dence intervals with the 
estimated European mean. ETH = ethanol (alcohol); THC = single tetrahydrocannabinol (cannabis); COC = single cocaine; AMP = single amphetamines; OPI 
= single illicit opiates; BDZ = single benzodiazepines; MOPI = single medicinal opioids; ZDR = single Z drugs; ETH + DRU = alcohol–drugs combinations; 
DRU + DRU = drug–drug combinations.
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the European mean was included in the confi dence interval 
for both countries.
Discussion
 Despite the fact that Belgium and The Netherlands are 
neighboring countries, the use of psychoactive substances in 
traffi c was far from similar. In Belgium, the use of alcohol 
and medicinal drugs in traffi c was higher than in The Nether-
lands, whereas the measured use of illicit substances in traf-
fi c was substantially higher in The Netherlands as compared 
with Belgium.
 The higher prevalence for alcohol in Belgium might be 
related to differences in the enforcement level. The enforce-
ment level for alcohol (number of alcohol tests per 100,000 
inhabitants) is estimated to be three to four times lower in 
Belgium than it is in The Netherlands (Veisten et al., 2011). 
Furthermore, cultural differences may be causing higher 
alcohol use in Belgian traffi c. For example, in Belgium, 
people tend to go out eating and drinking more often. This is 
refl ected in the number of restaurants per 10,000 inhabitants. 
In The Netherlands, the number of restaurants per 10,000 
inhabitants is approximately 35 (Bedrijfschap Horeca en 
Catering, 2011), whereas in the Flanders region—where 
about 60% of all Belgian inhabitants reside—the number 
of restaurants per 10,000 inhabitants is approximately 48 
(GUIDEA, 2011).
 The higher use of medicinal drugs in Belgium might 
be explained by a higher consumption of medicines in the 
general population. The average expenditure per person 
on medicines has been approximately 15%–20% higher in 
Belgium than in The Netherlands (Stichting Farmaceutische 
Kergetallen, 2011). The low expenditure in The Netherlands 
could partly be explained by a reluctant prescription policy 
of general practitioners.
 The relatively low prevalence of illicit drugs that was 
found in Belgium may be related to the high nonresponse 
level. It can be expected that drivers who had recently used 
an illicit drug would be less likely to participate in the study 
because they might be afraid that the test results would be 
used for legal purposes (drug driving legislation of 1999). 
A lower participation rate of drug-positive drivers would 
result in nonresponse bias. Based on a comparison of the 
detected prevalence of illicit substances among injured driv-
ers (Isalberti et al., 2011) and in the general population (Ra-
vera and De Gier, 2008), a higher prevalence of illicit drugs 
in Belgian traffi c would indeed be expected. The detected 
prevalence of illicit drugs in the general population was 
in fact comparable for the two countries, and the detected 
prevalence of illicit drugs among injured drivers was even 
higher for Belgium than it was for The Netherlands.
 Another indication of nonresponse bias can be derived 
from the odds ratios for illicit drugs that were calculated by 
Hels et al. (2011). Because of the low prevalence of illicit 
drugs in Belgium, only an adjusted odds ratio for getting 
seriously injured in a car crash could be calculated for can-
nabis. The Belgian odds ratio for cannabis (4.88) was ap-
proximately three times higher than the mean adjusted odds 
ratio (1.38) in Hels et al. (2011), which was based on the 
combined data of four included countries (Belgium, Den-
mark, The Netherlands, and Lithuania). If the mean adjusted 
odds ratio would be applied to the Belgian hospital data, the 
estimated prevalence for THC in Belgian traffi c is likely 
to be more comparable to the Dutch prevalence, although 
it is impossible to estimate the exact size of the potential 
nonresponse bias. Finally, keep in mind that, in this study, 
prevalence is based on predetermined limits of detection and 
not on limits of impairment.
Strengths and limitations
 The main strength of the present study is the similar de-
sign of roadside surveys performed in both Belgium and The 
Netherlands, which makes it possible to compare the results 
between the two countries as well as with the estimated 
European mean. By using equivalent cutoffs for drugs in 
blood and oral fl uid, the limitation of the comparability of 
the results when including two different body fl uid samples 
(blood and oral fl uid) was overcome. Another strength of 
this study is that blood and oral fl uid samples were used, not 
urine samples. Blood and oral fl uid can be used to detect re-
cent drug use, whereas urine samples may refl ect drug intake 
up to several days ago (Verstraete, 2004; Walsh et al., 2008). 
Furthermore, the study provides recent prevalence data of 
different psychoactive substances in the general driving 
population in Belgium and The Netherlands. For Belgium, 
this is the fi rst large-scale study that includes information on 
the prevalence of illicit drugs in traffi c.
 A limitation of this study is that the list of analyzed 
substances was not exhaustive. For example, there was no 
screening for gamma-hydroxybutyric acid (GHB), only seven 
benzodiazepines were screened for, and selective serotonin 
reuptake inhibitors were not included. The very high nonre-
sponse rate (52.1%) in Belgium is another limitation of the 
study because it could lead to nonresponse bias, especially 
for illicit drugs. Based on the assessment on possible con-
founding effects of nonresponse by comparing age, gender, 
and alcohol data, we can conclude that the possibility of 
nonresponse bias cannot be totally ruled out. Despite that 
there was a signifi cant difference (p < .001) in self-reported 
use of psychoactive substances other than alcohol between 
the response and the nonresponse group in The Netherlands, 
the actual bias seems to be very small because of the small 
size of the nonresponse group.
 Another limitation is that the studies in Belgium and The 
Netherlands did not collect oral fl uid in the same way. The 
collection procedure may have infl uenced the concentrations 
of the samples, as described in previous literature (Crouch, 
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2005; Langel et al., 2008; O’Neal et al., 2000; Verstraete et 
al., 2011a). Furthermore, a recent study (Houwing et al., 
submitted for publication) shows that THC concentrations 
in oral fl uid samples collected by spit tubes were on average 
1.9 times higher than THC concentrations collected by the 
StatSure collection device. These fi ndings indicate that the 
applied equivalent cutoff concentrations might have been too 
high for the Dutch study.
 Finally, despite the large sample size of the Belgian and 
Dutch prevalence study, the cell counts for some substances 
were small or even zero, which resulted in less stable com-
parisons between the estimates of both countries.
Conclusion
 The Netherlands and Belgium are neighboring countries. 
Nonetheless, statistical signifi cant differences are present in 
the prevalence of psychoactive substances in traffi c. In gen-
eral, medicinal drug use and alcohol were more frequently 
detected in Belgian traffi c, whereas illicit substances were 
more prevalent in The Netherlands. However, when compar-
ing the results of roadside surveys with hospital data and 
data from illicit drug use in the general population, it is 
likely that the observed prevalence of illicit drugs at the Bel-
gian roadside was underrepresented and that the prevalence 
of illicit drugs in Belgian traffi c is probably higher than the 
current results show.
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